AlphAIAlphAI — Financial news for AI agents
timothysykes.comOCT 282 min read$GMAB

Genmab (GMAB) Stock Surges As Rina-S And Petosemtamab Data Fuel Bull Run

Genmab A/S (GMAB) stock surged 28.9% on October 28, 2026, following positive data for its oncology drugs Rina-S and petosemtamab. The company reported strong Phase 3 results for Rina-S in ovarian cancer and promising Phase 2 data for petosemtamab in colorectal and head and neck cancers. Analysts upgraded GMAB, citing the potential of these drugs, with JPMorgan raising its price target significantly. GMAB's revenue is approximately $21.53B, with a P/E ratio of 155.11.

Original reporting
timothysykes.com
Published Oct 28, 2026, 4:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 4:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Genmab (GMAB) Stock Surges As Rina-S And Petosemtamab Data Fuel Bull Run — source image
Source · timothysykes.com
Decision brief

The 30-second read

$GMABBullishHigh
01

Why it matters

The data triggered a 28.9% intraday rally, analyst upgrades, and heightened market interest in the company's pipeline.

02

Market read

First‑report trial success creates immediate trading opportunity and may influence biotech sector sentiment.

03

What to watch

Potential regulatory delays or competition from other bispecific antibodies.

Relevance 8/10Novelty 9/10Timing: today pre‑market

Background

Genmab A/S (NASDAQ: GMAB) announced a Phase 3 win for Rina‑S in platinum‑resistant ovarian cancer and strong Phase 2 data for petosemtamab.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Phase 3 RINA‑S trial win and strong Phase 2 petosemtamab data drove a 28.9% intraday surge.

Expected impact

upward pressure as momentum traders chase the catalyst.

Evidence & confidence

First report of pivotal Phase 3 data and upgraded price targets create immediate buying incentive.

Market effects

Sector

Biotech sector may see broader rally on strong oncology data.

Regional

European biotech investors could see increased exposure to Genmab.

Global

Highlights the impact of late‑stage oncology trials on global biotech valuations.

Counterpoint

What could challenge this read

If later‑stage data falters, the high valuation could trigger a sharp correction.

Key entities

  • company
    Genmab A/S

    Biotech firm developing bispecific antibodies.

  • company
    Incyte

    Partner in KRAS G12D combination trial.

Read at source← All news

Related articles

OCT 28
$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

rttnews.com2 min
OCT 28
$GMABHigh

Genmab Stock (GMAB) Soars Over 30% on Strong Phase 3 Results for the Company’s Head and Neck Cancer Treatment

Genmab (GMAB) shares surged 30.54% after announcing positive Phase 3 trial results for petosemtamab combined with pembrolizumab in treating head and neck cancer. The treatment showed a 50% reduction in death risk. The company plans to seek regulatory approval. GMAB stock has gained 87.73% year-to-date and 54.3% over the past year. Analysts' average price target is $94.89, suggesting a 62.26% upside.

tipranks.com2 min
OCT 28
$GMABHigh

GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals — Here’s What Investors Need To Know

Genmab (GMAB) stock rose nearly 30% to an all-time high after positive Phase 3 trial results for its experimental head and neck cancer treatment, Petosemtamab, combined with Merck's Keytruda. The trial met primary goals, showing a 50% reduction in death risk and tripled tumor response odds. The company also reported positive Phase 3 results for its ovarian cancer drug, Rina-S, last week. Retail sentiment on Stocktwits turned bullish.

finance.yahoo.com2 min
OCT 28
$GMABHighAI 9/10

Genmab reports 50% lower death risk in Phase 3 trial

Genmab reported that its petosemtamab combination reduced the risk of death by 50% in a Phase 3 head-and-neck cancer trial, meeting both primary endpoints. The study involved 699 patients. Genmab's shares rose 15.22% to $51.47 on Wednesday. The company plans to discuss results with global regulators.

mugglehead.com2 min